- Home
- GOSS vs ORGO Comparison
GOSS vs ORGO Comparison
Compare GOSS & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- ORGO
- Stock Information
- Founded
- GOSS 2015
- ORGO 1985
- Country
- GOSS United States
- ORGO United States
- Employees
- GOSS N/A
- ORGO N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- GOSS Health Care
- ORGO Health Care
- Exchange
- GOSS Nasdaq
- ORGO Nasdaq
- Market Cap
- GOSS 501.2M
- ORGO 539.1M
- IPO Year
- GOSS 2019
- ORGO N/A
- Fundamental
- Price
- GOSS $2.37
- ORGO $3.97
- Analyst Decision
- GOSS Strong Buy
- ORGO Buy
- Analyst Count
- GOSS 6
- ORGO 3
- Target Price
- GOSS $8.60
- ORGO $7.33
- AVG Volume (30 Days)
- GOSS 3.0M
- ORGO 717.2K
- Earning Date
- GOSS 11-05-2025
- ORGO 11-06-2025
- Dividend Yield
- GOSS N/A
- ORGO N/A
- EPS Growth
- GOSS N/A
- ORGO N/A
- EPS
- GOSS N/A
- ORGO N/A
- Revenue
- GOSS $40,237,000.00
- ORGO $429,531,000.00
- Revenue This Year
- GOSS N/A
- ORGO $2.51
- Revenue Next Year
- GOSS $16.11
- ORGO $25.45
- P/E Ratio
- GOSS N/A
- ORGO N/A
- Revenue Growth
- GOSS N/A
- ORGO N/A
- 52 Week Low
- GOSS $0.66
- ORGO $2.61
- 52 Week High
- GOSS $3.60
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- GOSS 48.07
- ORGO 40.52
- Support Level
- GOSS $2.28
- ORGO $3.84
- Resistance Level
- GOSS $2.52
- ORGO $4.30
- Average True Range (ATR)
- GOSS 0.15
- ORGO 0.18
- MACD
- GOSS 0.02
- ORGO 0.00
- Stochastic Oscillator
- GOSS 62.79
- ORGO 23.64
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.